title: Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association.
authors.forename: Barbara S
authors.initials: BS
authors.lastname: Wiggins
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Saseen
authors.forename: Robert L
authors.initials: RL
authors.lastname: Page
authors.forename: Brent N
authors.initials: BN
authors.lastname: Reed
authors.forename: Kevin
authors.initials: K
authors.lastname: Sneed
authors.forename: John B
authors.initials: JB
authors.lastname: Kostis
authors.forename: David
authors.initials: D
authors.lastname: Lanfear
authors.forename: Salim
authors.initials: S
authors.lastname: Virani
authors.forename: Pamela B
authors.initials: PB
authors.lastname: Morris
mesh_terms: D000572:American Heart Association; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D000066491:Clinical Decision-Making; D015897:Comorbidity; D032921:Consensus; D004347:Drug Interactions; D050171:Dyslipidemias / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D019317:Evidence-Based Medicine; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics; D019338:Polypharmacy; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: AHA Scientific Statements; anti-arrhythmic agents; anticoagulants; calcium channel blockers; cardiovascular disease; drug-related side effects and adverse reactions; fenofibrate/fenofibric acid derivatives; gemfibrozil; hydroxymethylglutaryl-CoA reductase inhibitors; immunosuppressive agents